Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Impact on the population of different bone mineral density testing criteria and appropriateness of densitometries in the ESOSVAL cohort, Spain.

Hurtado I, Sanfélix-Gimeno G, Baixauli-Pérez C, Peiró S, Sanfélix-Genovés J.

J Clin Endocrinol Metab. 2014 Jan;99(1):142-50. doi: 10.1210/jc.2013-3448.

PMID:
24384018
2.

Impact of the NOGG and NOF Guidelines on the Indication of Bone Mineral Density in Routine Clinical Practice.

Kyriakos G, Vidal-Casariego A, Fernández-Martínez MN, Blanco-Suárez MD, Ballesteros-Pomar MD, Cano-Rodríguez I.

J Clin Densitom. 2015 Oct-Dec;18(4):533-8. doi: 10.1016/j.jocd.2015.08.001. Epub 2015 Sep 3.

PMID:
26343823
3.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

4.

Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry.

Cadarette SM, Jaglal SB, Murray TM, McIsaac WJ, Joseph L, Brown JP; Canadian Multicentre Osteoporosis Study.

JAMA. 2001 Jul 4;286(1):57-63.

PMID:
11434827
5.

Pharmacist Screening for Risk of Osteoporosis in Elderly Veterans.

Salvig BE, Gulum AH, Walters SA, Edwards LB, Fourakre TN, Marvin SC, McKenzie MS, Moseley MV, Ansari IJ.

Consult Pharm. 2016;31(8):440-9. doi: 10.4140/TCP.n.2016.440.

PMID:
27535079
6.

Bone mineral density screening and its accordance with Canadian clinical practice guidelines from 2000-2013: an unchanging landscape in Saskatchewan, Canada.

McLeod KM, Johnson S, Charturvedi R, St Onge J, Lionel A, Verma A.

Arch Osteoporos. 2015;10:227. doi: 10.1007/s11657-015-0227-2. Epub 2015 Jul 15.

PMID:
26173601
7.

Selection of women aged 50-64 yr for bone density measurement.

Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA; Manitoba Bone Density Program.

J Clin Densitom. 2013 Oct-Dec;16(4):570-8. doi: 10.1016/j.jocd.2013.01.004. Epub 2013 Feb 26.

PMID:
23452870
8.

What is the number of older Canadians needed to screen by measurement of bone density to detect an undiagnosed case of osteoporosis? a population-based study from CaMos.

Sawka AM, Papaioannou A, Josse RG, Murray TM, Ioannidis G, Hanley DA, Prior JC, Thabane L, Papadimitropoulos EA, Gafni A, Pickard L, Anastassiades T, Kirkland S, Adachi JD; CaMos Research Group.

J Clin Densitom. 2006 Oct-Dec;9(4):413-8. Epub 2006 Sep 1.

PMID:
17097526
9.

Interest of a prescreening questionnaire to reduce the cost of bone densitometry.

Ben Sedrine W, Broers P, Devogelaer JP, Depresseux G, Kaufman JM, Goemaere S, Reginster JY.

Osteoporos Int. 2002 May;13(5):434-42.

PMID:
12086356
10.

Use of FRAX as a determinant for risk-based osteoporosis screening may decrease unnecessary testing while improving the odds of identifying treatment candidates.

Edwards FD, Grover ML, Cook CB, Chang YH.

Womens Health Issues. 2014 Nov-Dec;24(6):629-34. doi: 10.1016/j.whi.2014.06.006. Epub 2014 Aug 12.

PMID:
25128036
11.

Osteoporosis screening for men: are family physicians following the guidelines?

Cheng N, Green ME.

Can Fam Physician. 2008 Aug;54(8):1140-1141, 1141.e1-5.

12.
13.

The role of hip and chest radiographs in osteoporotic evaluation among south Indian women population: a comparative scenario with DXA.

Kumar DA, Anburajan M.

J Endocrinol Invest. 2014 May;37(5):429-40. doi: 10.1007/s40618-014-0074-9. Epub 2014 Apr 16.

PMID:
24737214
14.

Opportunistic Osteoporosis Screening: Addition of Quantitative CT Bone Mineral Density Evaluation to CT Colonography.

Ziemlewicz TJ, Binkley N, Pickhardt PJ.

J Am Coll Radiol. 2015 Oct;12(10):1036-41. doi: 10.1016/j.jacr.2015.04.018.

PMID:
26435117
15.

Treatment implications for men when switching from male to female bone mineral density reference data: the Manitoba Bone Density Program.

Leslie WD, Majumdar SR.

J Clin Densitom. 2013 Oct-Dec;16(4):537-42. doi: 10.1016/j.jocd.2013.07.004. Epub 2013 Oct 3.

PMID:
24090643
16.
17.

Osteoporosis Management in a Real Clinical Setting: Heterogeneity in Intervention Approach and Discrepancy in Treatment Rates when Compared with the NOGG and NOF Guidelines.

Kyriakos G, Vidal-Casariesgo A, Quiles-Sánchez LV, Urosa-Maggi JA, Calleja-Fernández A, Hernández-Moreno A, Ballesteros-Pomar MD, Cano-Rodriguez I.

Exp Clin Endocrinol Diabetes. 2016 Sep;124(8):466-473. Epub 2016 May 24.

PMID:
27219881
18.

Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia Region (Spain). The ESOSVAL-AD study.

Sanfélix-Gimeno G, Sanfélix-Genovés J, Peiró S, Hurtado I, Trillo JL, Usó R, Ruiz VG, de la Torre MP, Ferreros I.

BMC Musculoskelet Disord. 2011 Aug 3;12:178. doi: 10.1186/1471-2474-12-178.

19.

Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.

Sanfélix-Genovés J, Sanfélix-Gimeno G, Peiró S, Hurtado I, Fluixà C, Fuertes A, Campos JC, Giner V, Baixauli C.

Osteoporos Int. 2013 Mar;24(3):1045-55. doi: 10.1007/s00198-012-2018-6. Epub 2012 May 23.

PMID:
22618269
20.

Supplemental Content

Support Center